Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine

被引:60
作者
Kalow, W. [1 ]
机构
[1] Univ Toronto, Dept Pharmacol, Toronto, ON M5S 1A8, Canada
关键词
individuals; populations; environment multifactorial variation; gene expression;
D O I
10.1038/sj.tpj.6500361
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Pharmacogenetics arose with studies of single genes, which had major effects on the action of particular drugs. It turned into pharmacogenomics through realization that the controls of most drug responses are multifactorial. Then, variable gene expression posed new problems, for example what do drugs do to genes, or how useful is any genetic pretesting of a person? A common disease may be caused by different groups of genes in different people, who therefore require different drugs for treatment. Personlized medicine is currently represented by a physician's attention to a patients age, sex, or ethnic backround, that is groups showing smaller genetic variation than is typical for general humanity. Occasionally, there is also the use of single-gene pretesting of a patient before drug administration. Over time, improvements in multigenic testing promise to increase the role of personalized medicine. However, the many pharmacogenomic complexities, and particularly time-dependent changes of gene expression, will never allow personalized medicine to become an error-free entity.
引用
收藏
页码:162 / 165
页数:4
相关论文
共 58 条
[11]   Small RNAs make big splash [J].
Couzin, J .
SCIENCE, 2002, 298 (5602) :2296-2297
[12]   DEFECTIVE N-OXIDATION OF SPARTEINE IN MAN - NEW PHARMACOGENETIC DEFECT [J].
EICHELBAUM, M ;
SPANNBRUCKER, N ;
STEINCKE, B ;
DENGLER, HJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 16 (03) :183-187
[13]   Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty [J].
Ershler, WB ;
Keller, ET .
ANNUAL REVIEW OF MEDICINE, 2000, 51 :245-270
[14]   Methylation and demethylation in the regulation of genes, cells, and responses in the immune system [J].
Fitzpatrick, DR ;
Wilson, CB .
CLINICAL IMMUNOLOGY, 2003, 109 (01) :37-45
[15]   Multilocus effects of the renin-angiotensin-aldosterone system genes on blood pressure response to a thiazide diuretic [J].
Frazier, L ;
Turner, ST ;
Schwartz, GL ;
Chapman, AB ;
Boerwinkle, E .
PHARMACOGENOMICS JOURNAL, 2004, 4 (01) :17-23
[16]  
GARROD AE, INBORN FACTORS DIS E
[17]  
Haldane J. B. S., 1949, Ricerca Scientifica Suppl, P68
[18]   Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose [J].
Herman, D ;
Locatelli, I ;
Grabnar, I ;
Peternel, P ;
Stegnar, M ;
Mrhar, A ;
Breskvar, K ;
Dolzan, V .
PHARMACOGENOMICS JOURNAL, 2005, 5 (03) :193-202
[19]   Transporters and drug therapy: Implications for drug disposition and disease [J].
Ho, RH ;
Kim, RB .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (03) :260-277
[20]   Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity [J].
Ingelman-Sundberg, M .
PHARMACOGENOMICS JOURNAL, 2005, 5 (01) :6-13